Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data

CHICAGO (Reuters) - Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday. | 08:21am

Related Keywords

New York ,United States ,Chicago ,Illinois ,American ,Jane Healy ,Vinod Balachandran ,Julie Steenhuysen ,Merck Moderna ,Caroline Humer ,Merck Keytruda ,Roche Tecentriq ,Andrew Allen ,Gritstone Bio Inc ,Researchers At Memorial Sloan Kettering Cancer Center ,American Society Of Clinical Oncology ,American Society ,Clinical Oncology ,Memorial Sloan Kettering Cancer Center ,Bill Berkrot , ,